Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune modulation therapy in heart failure.

Lisa M Mielniczuk1, Kenneth L Baughman

  • 1Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.

Congestive Heart Failure (Greenwich, Conn.)
|April 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) Trial-IMAGE HF Project 1A.

CJC open·2025
Same author

Management of Ischemic Heart Disease in Patients With Heart Failure: JACC: Heart Failure Position Statement.

JACC. Heart failure·2025
Same author

Sex Differences in Access to Physician Care Following a New Diagnosis of Heart Failure in the Ambulatory Setting.

The Canadian journal of cardiology·2025
Same author

Test-retest Assessment of Biventricular Myocardial Oxidative Metabolism and Perfusion in Pulmonary Hypertension Patients Using <sup>11</sup>C-acetate PET Imaging: A Pilot Study.

Molecular imaging and biology·2025
Same author

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study.

European journal of heart failure·2024
Same author

Prescription Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes and Heart Failure With Reduced Ejection Fracture Admitted to a Tertiary Care Centre in Ontario, Canada.

Canadian journal of diabetes·2024
Same journal

Serum cystatin C as a biomarker of cardiac diastolic dysfunction in patients with cardiac disease and preserved ejection fraction.

Congestive heart failure (Greenwich, Conn.)·2013
Same journal

Thiamine supplementation for the treatment of heart failure: a review of the literature.

Congestive heart failure (Greenwich, Conn.)·2013
Same journal

Preload reserve is restored in patients with decompensated chronic heart failure who respond to treatment.

Congestive heart failure (Greenwich, Conn.)·2013
Same journal

Decreased readmissions and improved quality of care with the use of an inexpensive checklist in heart failure.

Congestive heart failure (Greenwich, Conn.)·2013
Same journal

Catheter ablation of atrial flutter in patients with left ventricular assist device improves symptoms of right heart failure.

Congestive heart failure (Greenwich, Conn.)·2013
Same journal

Prognosis of morbid obesity patients with advanced heart failure.

Congestive heart failure (Greenwich, Conn.)·2013
See all related articles

Inflammation contributes to heart failure progression. Immunomodulatory therapies show promise but require further research to identify effective strategies for reducing heart failure morbidity and mortality.

Area of Science:

  • Cardiology
  • Immunology
  • Pathophysiology

Background:

  • Inflammation is increasingly recognized as a key factor in congestive heart failure (CHF) development and progression.
  • Inflammatory processes impact cardiac contractility, hypertrophy, apoptosis, and myocardial remodeling in heart failure.
  • The rising prevalence of heart failure necessitates novel therapeutic approaches.

Purpose of the Study:

  • To explore the role of inflammation in congestive heart failure pathogenesis.
  • To evaluate the potential of immunomodulatory therapies for heart failure patients.
  • To identify research needs for optimizing immunomodulatory treatment strategies.

Main Methods:

  • Review of existing evidence on inflammation in heart failure.
  • Analysis of studies investigating immunomodulatory interventions.

Related Experiment Videos

  • Identification of knowledge gaps in the immunopathogenesis of heart failure.

    • Main Results:

    • Evidence supports inflammation's pathogenic role in heart failure.
    • Immunomodulatory therapy presents a potential treatment avenue.
    • Current understanding of precise mechanisms and patient selection requires further investigation.

    Conclusions:

    • Targeted immunomodulatory strategies may offer benefits for heart failure patients.
    • Further research is crucial to define key immunopathogenic factors.
    • Identifying responsive patient populations and developing consistent management strategies are essential for reducing heart failure morbidity and mortality.